UCART-123

N/A

Report date: 2024/12/31 14:01:40

Base Information

Drug NameUCART-123
Drug Alias NameUCART-123UCART-123v1.2
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellectis Sa
China Registration ClassN/A

Develop Information

Active CompaniesCellectis Sa
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsBlastic Plasmacytoid Dendritic Cell Neoplasm

Other Information

ATC CodeN/A
Related LinksN/A